Radiopharm Theranostics files governance 6-K

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange.

Rhea-AI Filing Summary

Radiopharm Theranostics Limited submitted a Form 6-K as a foreign private issuer to provide U.S. investors with information it released on the Australian Securities Exchange. The filing furnishes as an exhibit a Public Notice dated September 17, 2025 titled “Corporate Governance Statement and Appendix 4G.”

The attached materials relate to the company’s corporate governance disclosures and associated compliance appendix. The Form 6-K and its exhibit are furnished, not filed, under U.S. securities laws, meaning they are not automatically incorporated by reference into other Securities Act filings unless specifically referenced.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Radiopharm Theranostics (RDPTF) report in this Form 6-K?

The company furnished a Form 6-K to provide a copy of an Australian Securities Exchange Public Notice titled “Corporate Governance Statement and Appendix 4G” dated September 17, 2025.

What exhibit is included with Radiopharm Theranostics' September 2025 Form 6-K?

The Form 6-K includes exhibit 99.1, described as the company’s Corporate Governance Statement and Appendix 4G.

Is the Radiopharm Theranostics Form 6-K considered filed or furnished under the Exchange Act?

The Form 6-K states that it, including the exhibit, shall not be deemed to be “filed” for purposes of the Exchange Act and is instead furnished.

Will this Radiopharm Theranostics 6-K be automatically incorporated into other SEC filings?

No. The document explains it will not be incorporated by reference into any Securities Act filing unless specifically referenced in that filing.

Who signed the Radiopharm Theranostics Form 6-K and in what capacity?

The Form 6-K was signed on September 17, 2025 by Phillip Hains in his capacity as Company Secretary of Radiopharm Theranostics Limited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/17/2025 - 09:23 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of September 2025

Commission File Number: 001-41621

RADIOPHARM THERANOSTICS LIMITED

(Name of Registrant)

Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐       No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

RADIOPHARM THERANOSTICS LIMITED

EXPLANATORY NOTE

Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 17, 2025 titled:

- “Corporate Governance Statement and Appendix 4G”

A copy of the Public Notice is attached as an exhibit to this report on Form 6-K.

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

1

EXHIBITS

Exhibit Number		Description
99.1		Corporate Governance Statement and Appendix 4G

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RADIOPHARM THERANOSTICS LIMITED
Date: September 17, 2025	By:	/s/ Phillip Hains
		Phillip Hains
		Company Secretary

3